SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at four upcoming investor conferences in May and June. 2025 Bank of America Health Care Conference Location – Las Vegas, NV Fireside Chat – Wednesday, May... Read More

Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (“PROCEPT”), a surgical robotics company whose mission is to revolutionize BPH treatment globally, today announced an extensive lineup of scientific... Read More

SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% compared to the... Read More

SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Aria Resort in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time . Guests are... Read More

SAN JOSE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced its Aquablation therapy was evaluated in the independent, investigator-initiated WATER III trial. This study compared Aquablation therapy to laser enucleation for treating large prostates,... Read More

SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am... Read More

SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue of approximately $68.2 million for the fourth quarter of 2024, an increase of... Read More

SAN JOSE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2024 after market close on Tuesday, February 25, 2025. The Company’s management will host a corresponding conference call beginning at... Read More

SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30... Read More

SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of $91.00 per share, before underwriting... Read More

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock. A selling stockholder also expects to grant the... Read More

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024. Recent Highlights Total revenue of $58.4 million for the third quarter of 2024, an increase of 66% compared to the... Read More

SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2024 before market open on Monday, October 28, 2024. The Company’s management will host a corresponding conference call... Read More

A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in How Urologists Might Treat Localized Prostate Cancer SAN JOSE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient... Read More

SAN JOSE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, September 4 at 1:30... Read More

SAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning,... Read More

SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% compared to the... Read More

SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company’s management will host a corresponding conference call... Read More

SAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has established a new Current Procedural Terminology (“CPT”) Category I code for transurethral waterjet resection of prostate tissue... Read More

SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m.... Read More

SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20... Read More

SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data showcasing the benefits of Aquablation therapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) at both academic and commercial... Read More

SAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2024. Re cent Highlights Total revenue of $44.5 million for the first quarter of 2024, an increase of 83% compared to the... Read More

SAN JOSE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the presentation of a late breaking post-market survey at the Japanese Urological Association (JUA) Annual Meeting on positive Aquablation therapy outcomes for men in Japan with... Read More

SAN JOSE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that 12 abstracts highlighting its Aquablation therapy for the treatment of benign prostatic hyperplasia (BPH) will be presented at the American Urological Association (AUA) Annual Meeting in San... Read More

SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, May 3, 2024, at the Grand Hyatt Hotel in San Antonio, TX at the American Urological Association Annual Meeting from 8:00am to 9:30am Central... Read More

SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 1, 2024. The Company’s management will host a corresponding conference call... Read More

SAN JOSE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2023. Recent Highlights Total revenue of approximately $43.6 million for the fourth quarter of 2023, an increase of 83% compared to... Read More

SAN JOSE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 44th Annual TD Cowen Health Care Conference in Boston. Management is scheduled to present on Tuesday, March 5 at 12:50 p.m. Eastern Time.... Read More

SAN JOSE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the quarter and fiscal year ended December 31, 2023. Preliminary, Unaudited Revenue Highlights: Total revenue for the fourth quarter of 2023 is... Read More

SAN JOSE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 35th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, November 29 at 1:30... Read More

SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2023. Recent Highlights Total revenue of $35.1 million for the third quarter of 2023, an increase of 72% compared to the... Read More

SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (NASDAQ: PRCT), a surgical robotics global leader, is pleased to announce that the National Institute for Health and Care Excellence (NICE) has bestowed its strongest endorsement, the "standard arrangements" recommendation, on Aquablation ® therapy for the treatment of benign prostatic hyperplasia (BPH). NICE plays a pivotal role in... Read More

SAN JOSE, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a surgical robotics company focused on developing transformative solutions in urology, proudly announces the grand opening of its state-of-the-art global corporate headquarters in San Jose, California.... Read More

REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today the Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to investigate the safety and efficacy of Aquablation therapy for prostate cancer. The IDE approval allows PROCEPT BioRobotics to initiate a... Read More

REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today that it has successfully completed the first commercial Aquablation ® therapy procedures in Japan. The procedures were carried out at two premier medical institutions, in association with the 100 patient post-market surveillance study.... Read More

REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2023 Wells Fargo Healthcare Conference in Boston. Management is scheduled to present on Thursday, September 7 at 3:00 p.m. Eastern... Read More

EVANSTON, Ill., Aug. 16, 2023 (GLOBE NEWSWIRE) -- NorthShore University HealthSystem (NorthShore) and PROCEPT BioRobotics ® announce a significant milestone in access to treatment of Benign Prostatic Hyperplasia (BPH). NorthShore’s Highland Park Hospital has become the first hospital in the United States to install a second AquaBeam Robotic System that delivers the cutting-edge Aquablation ® therapy procedure, which removes... Read More

REDWOOD CITY, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an upsized underwritten public offering of 4,422,169 shares of its common stock at a public offering price of $33.92 per share, before underwriting... Read More

REDWOOD CITY, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $125,000,000 of shares of its common stock. PROCEPT BioRobotics also expects to grant the underwriters a 30-day... Read More

REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2023. Recent Highlights Total revenue of $33.1 million for the second quarter of 2023, an increase of 98% compared to the... Read More

REDWOOD CITY, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2023 before market open on Thursday, July 27, 2023. The Company’s management will host a corresponding conference call... Read More

5-Year results from WATER II when combined with 5-year results from the original WATER study demonstrate that Aquablation therapy provides long-term symptom relief while preserving sexual function for patients with small and large prostates. The study concluded that Aquablation therapy: Is safe, effective and durable with symptoms metrics demonstrating large immediate and sustained improvements for patients 96.3% of patients... Read More

REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- PROCEPT ® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2023. Recent Highlights Total revenue of $24.4 million for the first quarter of 2023, an increase of 72% compared to... Read More

REDWOOD CITY, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- PROCEPT ® BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2023 before market open on Thursday, April 27, 2023. The Company’s management will host a corresponding conference... Read More

REDWOOD CITY, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- PROCEPT ® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that United Healthcare published an update to its Prostate Surgeries and Interventions Policy Bulletin that states Aquablation ® therapy is proven and medically necessary for... Read More

REDWOOD CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 28, 2023, in Chicago at the American Urological Association Annual Meeting from 8:00am to 9:30am Central Time. This... Read More

REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation today announced Aquablation Therapy received a MedTech Innovation Briefing (MIB) from the National Institute for Health Care Excellence (NICE), for benign prostate hyperplasia (BPH) in the United Kingdom. NICE has recognized Aquablation Therapy is as effective as transurethral resection of the prostate (TURP) for the removal of prostate... Read More

REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- PROCEPT ® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming Virtual Key Bank Life Sciences & MedTech Investor Forum. Management is scheduled to present on Tuesday, March 21 at... Read More

REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PROCEPT ® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2022. Recent Highlights Total revenue of $75.0 million for full year 2022, an increase of 118% compared to 2021 Total revenue of... Read More

REDWOOD CITY, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- PROCEPT ® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 43rd Annual Cowen Health Care Conference in Boston. Management is scheduled to present on Tuesday, March 7 at 12:50 p.m.... Read More

REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the quarter and fiscal year ended December 31, 2022. Preliminary, Unaudited Revenue Highlights: Total revenue for the fourth quarter of 2022 is... Read More